Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis

Chang Yue; Zhang Wen; Liu QinYu; Zhang Qing; Chen Kai; Li Hai

doi:10.3969/j.issn.1001-5256.2019.05.024

Volume 35 Issue 5

May 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(5): 1057-1060

PDF( 2436 KB)

Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.05.024

Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces

Research funding:

Received Date: 2018-11-26
Published Date: 2019-05-20

Abstract

Abstract

Objective To conduct a meta-analysis of the articles on the effect of silibinin on aminotransferases in patients with nonalcoholic fatty liver disease ( NAFLD) , and to investigate the liver-protecting effect of silibinin in patients with NAFLD. Methods CNKI, Wanfang Data, VIP, SinoMed, PubMed, MEDLINE, Embase, and ScienceDirect were searched for randomized controlled trials ( RCTs) on the treatment of NAFLD patients with silibinin, The articles were screened according to inclusion and exclusion criteria, and then quality assessment and data extraction were performed. RevMan 5. 3 was used to perform the meta-analysis. Results A total of 8 articles with 665 patients were included. After 8 weeks to 3 months of silibinin treatment, there were significant reductions in the serum levels of alanine aminotransferase ( ALT) ( weighted mean difference [WMD]=-11. 60, 95% confidence interval [CI]:-18. 68 to-4. 51, P = 0. 001) and aspartate aminotransferase ( AST) ( WMD =-11. 56, 95% CI:-16. 93 to-6. 18, P < 0. 001) . Conclusion Silibinin can significantly reduce the serum levels of ALT and AST in patients with NAFLD.
- non-alcoholic fatty liver disease,
- silibinin,
- transaminases,
- Meta-analysis

FullText(HTML)

References(21)

References

[1] GEORGE J, ANSTEE Q, RATZIU V, et al. NAFLD:The evolving landscape[J]. J Hepatol, 2018, 68 (2) :227-229.

[2] ROSSO C, MEZZABOTTA L, GAGGINI M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease[J]. Hepatology, 2016, 63 (1) :107-116.

[3] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67 (1) :328-357.

[4] ZHAO ZH, LIU XL, FAN JG. Research on the natural history of non-alcoholic fatty liver disease should be taken seriously[J]. Chin J Hepatol, 2017, 25 (2) :81-84. (in Chinese) 赵泽华, 刘晓琳, 范建高.重视非酒精性脂肪性肝病自然史的研究[J].中华肝脏病杂志, 2017, 25 (2) :81-84.

[5] CHAN WK, MUSTAPHA RNR, MAHADEVA S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15 (12) :1940-1949.

[6] LU XL, DONG L, ZHANG KX, et al. Observation on the therapeutic efficacy of silibinin capsules for patients with fatty liver disease[J]. J Pract Hepatol, 2008, 11 (6) :398-400. (in Chinese) 鲁晓岚, 董蕾, 张宽学, 等.水飞蓟宾治疗脂肪肝的疗效观察[J].实用肝脏病杂志, 2008, 11 (6) :398-400.

[7] MA ZQ. Clinical analysis of silibin-phosphatidylcholine treated the 61 cases alcoholicfattyliver[J]. Pract J Card Cereb Pneumal Vasc Dis, 2008, 4 (16) :29-30. (in Chinese) 马臻奇.水飞蓟宾-磷脂酰胆碱治疗酒精性脂肪肝61例临床分析[J].实用心脑肺血管病杂志, 2008, 4 (16) :29-30.

[8] HAJIAGHAMOHAMMADI AA, ZIAEE A, OVEISI S, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease:A randomized controlled pilot study[J].Hepat Mon, 2012, 12:e6099.

[9] HASHEMI SJ, HAJIANI E, SARDABI EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver[J]. Hepat Mon, 2009, 9:265-270.

[10] HUANG HX. Observation of therapeutic effects of Silibinin Capsules to treat sixty cases of nonalcoholic fatty liver disease[J].China Med Herald, 2011, 8 (7) :62-63. (in Chinese) 黄红霞.水林佳 (水飞蓟宾-磷脂复合物) 治疗非酒精性脂肪性肝病60例临床疗效观察[J].中国医药导报, 2011, 8 (7) :62-63.

[11] MOHESN M, AMIRMANSOOR R, MOHAMMAD P, et al. Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases[J]. Govaresh, 2013, 18 (3) :181-185.

[12] SOLHI H, GHAHREMANI R, KAZEMIFAR AM, et al. Silymarin in treatment of non-alcoholic steatohepatitis:A randomized clinical trial[J]. Caspian J Intern Med, 2014, 5:9-12.

[13] LI Y. The Clinical efficacy of silibinin and its influence to life quality of NAFLD patients[J]. Inf Tradit Chin Med, 2017, 34 (4) :88-91. (in Chinese) 李颖.水飞蓟宾治疗非酒精性脂肪性肝病的疗效分析及对患者生存质量影响的研究[J].中医药信息, 2017, 34 (4) :88-91.

[14] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol, 2018, 34 (12) :2515-2519. (in Chinese) 李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志, 2018, 34 (12) :2515-2519.

[15] GUO ZQ, WANG QY, QI XS, et al. Recommenda tions for the diagnosis and management of nonalcoholic fatty Liver disease:Practice guidance from the American Association for the Study of Liver Diseases (2017) [J]. J Clin Hepatol, 2017, 33 (12) :2275-2277. (in Chinese) 郭泽淇, 王倩怡, 祁兴顺, 等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2275-2277.

[16] VECCHIONE G, GRASSELLI E, VOCI A, et al. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells[J]. World J Gastroenterol, 2016, 22 (26) :6016-6026.

[17] FENG ZM, CHENG SQ. Effects of silibinin combined with lamivudine treating the liver cirrhosis with active hepatitis B[J].Chin Gen Pract, 2007, 10 (8) :659-661. (in Chinese) 冯自明, 程书权.水飞蓟宾联合拉米夫定治疗慢性乙型肝炎活动性肝硬化疗效分析[J].中国全科医学, 2007, 10 (8) :659-661.

[18] LYU CJ, LI H, YANG ZF. Role of lipid metabolism in nonalcoholic fatty hepatopathy[J]. J Log Univ CAPF:Med Sci, 2013, 22 (2) :158-160. (in Chinese) 吕成娇, 李海, 杨占福.脂质代谢在非酒精性脂肪性肝病发病机制中的作用研究现状[J].武警后勤学院学报:医学版, 2013, 22 (2) :158-160.

[19] LI QQ, ZHOU Q, NIU JQ. New advances in pharmacological mechanism of silymarin and re-investigation of its clinical values[J]. J Clin Hepatol, 2015, 31 (2) :315-316. (in Chinese) 李青权, 周强, 牛俊奇, 等.水飞蓟素药理机制新进展及临床价值再探讨[J].临床肝胆病杂志, 2015, 31 (2) :315-316.

[20] HE XJ, YANG ZY, DU XL, et al. Clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease[J]. China Med Herald, 2017, 14 (14) :123-125, 130. (in Chinese) 贺小军, 杨振宇, 杜锡林, 等.阿托伐他汀钙联合水飞蓟宾治疗非酒精性脂肪肝的临床效果[J].中国医药导报, 2017, 14 (14) :123-125, 130.

[21] LIANG MX, CAI XH. Current status of pharmacokinetics and clinical study of silibinin-phospholipid complex[J]. Chin J New Drugs, 2010, 19 (19) :1778-1780. (in Chinese) 梁明欣, 蔡雪虹.水飞蓟宾-磷脂复合物的药动学及临床研究现状[J].中国新药杂志, 2010, 19 (19) :1778-1780.

Relative Articles

[1]	Yuzhen YU, Liewang QIU, Ping HE. Association between Helicobacter pylori and nonalcoholic fatty liver disease： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1360-1369. doi: 10.12449/JCH240713
[2]	Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
[3]	Zhang BaoHua, Yang Ya, Gong JianPing. Clinical effect and safety of nutritional support after pancreaticoduodenectomy: A Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1231-1236. doi: 10.3969/j.issn.1001-5256.2018.06.020
[4]	Sun YuanPei, Guo XiaoXia. Clinical effect of probiotics in treatment of liver cirrhosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(1): 73-79. doi: 10.3969/j.issn.1001-5256.2018.01.015
[5]	Hou Jie, Liu LiXin. Effect of probiotics in treatment of nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2624-2630. doi: 10.3969/j.issn.1001-5256.2018.12.023
[6]	Wu Yue, Huang LiPing. Value of real-time shear wave elastography in evaluating classification of liver fibrosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(9): 1717-1721. doi: 10.3969/j.issn.1001-5256.2017.09.017
[7]	Mo XiaoLi, Liu Jie, Zhu JiaYu, Chen Chuang, Ou Jie, Mao SuFei. Value of transforming growth factor-β1 in diagnosis of primary liver cancer:a meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(5): 864-868. doi: 10.3969/j.issn.1001-5256.2017.05.014
[8]	Zhao Jian, Li Wei, Liang CaiQuan, Yao DingKang. Liver cirrhosis and the risk of fracture: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(6): 1112-1115. doi: 10.3969/j.issn.1001-5256.2017.06.019
[9]	Li Mi, Nie QingHe. Accuracy of Fibro Scan for diagnosis of primary liver cancer: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(2): 312-316. doi: 10.3969/j.issn.1001-5256.2016.02.023
[10]	Mao HaiYing, Kang Tao, Yao Ling, Chen Qin. Efficacy of glycyrrhizin in patients with chronic severe hepatitis B:a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(1): 63-67. doi: 10.3969/j.issn.1001-5256.2015.01.014
[11]	Zhang WenWen, Qi XingShun, Guo XiaoZhong. Mirabilite umbilical compress in treatment of ascites in liver cirrhosis: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 947-950. doi: 10.3969/j.issn.1001-5256.2015.06.028
[12]	Li Xia, Shi YongYu. Correlation between interleukin-6 and primary hepatocellular carcinoma: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 936-942. doi: 10.3969/j.issn.1001-5256.2015.06.026
[13]	Fan YunYu, Sun LingYun. Association between smoking and risk of primary biliary cirrhosis: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1625-1629. doi: 10.3969/j.issn.1001-5256.2015.10.016
[14]	Yu Yuan, Yang ZongGuo, Chen ChiChi, Lu YunFei, Xu QingNian, Chen XiaoRong. Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1630-1633. doi: 10.3969/j.issn.1001-5256.2015.10.017
[15]	Zhang YuHuai, Luo ZhangJiang. Efficacy and safety of octreotide in treatment of hepatocellular carcinoma: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 922-926. doi: 10.3969/j.issn.1001-5256.2015.06.023
[16]	Zhou LiJun. Clinical efficacy of Liuweiwuling tablets in treatment of non- alcoholic fatty liver disease: a meta- analysis[J]. Journal of Clinical Hepatology, 2015, 31(7): 1068-1072. doi: 10.3969/j.issn.1001-5256.2015.07.017
[17]	Yin TianSheng, Yi YaYang, Mao XiXian, Li DeWei. Meta-analysis of risk factors for posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1009-1014. doi: 10.3969/j.issn.1001-5256.2014.10.009
[18]	Ye Gang, Ma Yu, Tang ChengJia, Du ChengYou. Clinical outcomes of laparoscopic hepatectomy and open hepatectomy for hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2013, 29(3): 184-190.
[19]	Chen XiaoHong, Wu ZongYing, Wang YiPing, Ceng Chao, Pan Tao. Fatality and adverse event rates of prostaglandin E in treating acute liver failure: a meta- analysis[J]. Journal of Clinical Hepatology, 2013, 29(9): 681-684. doi: 10.3969/j.issn.1001-5256.2013.09.012
[20]	Song LiWen, Zhao GuiMing, Cao WuKui, Lu ChengZhen. Meta analysis of the comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(9): 955-961.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	郭思瑞，邝咏梅，何笑荣，徐文峰. 水飞蓟宾胶囊保肝作用的药学研究进展. 中国医院用药评价与分析. 2024(01): 116-118+123 .
2.	孔祥鹏，药雅俊，任海琴，裴妙荣，李慧峰. 基于保肝活性的大黄硝石汤组分配伍优化及药效评价. 医药导报. 2024(06): 874-884 .
3.	谢丽锋，徐建荣. 自拟健脾祛湿汤联合水飞蓟宾胶囊治疗脾虚湿热型非酒精性脂肪性肝炎临床观察. 浙江中西医结合杂志. 2024(06): 526-528 .
4.	王依希，季盛，耿坚，卓蕴慧. 磁共振脂肪定量技术在非酒精性脂肪性肝病患者小柴胡汤加减联合水飞蓟素胶囊治疗疗效评估中的价值. 中国医学装备. 2024(09): 65-70 .
5.	陈忆青，陈小莹. 双歧杆菌三联活菌胶囊联合水飞蓟宾治疗非酒精性脂肪性肝炎患者疗效及对肠道菌群的影响. 中国药物与临床. 2024(23): 1539-1543 .
6.	魏文迪，蒋明芹. 复合益生菌联合水飞蓟宾胶囊治疗非酒精性脂肪肝的临床效果. 临床合理用药. 2023(16): 78-81 .
7.	张相敏. 疏肝健脾化浊汤及安络化纤丸辅治非酒精性脂肪肝临床观察. 实用中医药杂志. 2022(06): 993-994 .
8.	赵红，吕芳芳，桑荣霞，王晓忠，李志惠，谢雯. 水飞蓟宾胶囊治疗药物性肝损伤的临床疗效. 甘肃医药. 2021(06): 490-493 .
9.	张彤彤，鲁晓岚. 保肝药在代谢相关脂肪性肝病中的应用. 世界临床药物. 2021(08): 612-618 .
10.	李春晓. 非酒精性脂肪肝发病机制及中药治疗进展. 光明中医. 2020(12): 1947-1950 .
11.	许炎煌，范建高. 非酒精性脂肪性肝病治疗药物研究进展. 上海医药. 2020(19): 3-6+11 .
12.	梁栋，张鼎，仓宝成. 壳脂胶囊联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病. 实用医药杂志. 2020(12): 1088-1089+1099 .

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2095) PDF downloads(452)

Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.05.024